Articles in General Practice

This week in evidence-based medicine
Helicobacter
Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
Auttajaroon, Vilaichone, Chotivitayatarakorn, et al.
Scandinavian Journal of Gastroenterology
Treatment of newly-diagnosed gastroesophageal reflux disease: a nationwide register-based cohort study
Ljungdalh, Rubin, Durup, et al.
European Journal of Heart Failure
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
Shen, Rørth, Cosmi, et al.
Expert Review of Clinical Immunology
The relationship between B7 homologous 1 with interleukin-4, interleukin-17 and interferon gamma in patients with allergic rhinitis
Nasiri Kalmarzi, Fakhimi, Manouchehri, et al.
Pediatric Diabetes
Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self-management behaviors in adolescents with type 1 diabetes
Wagner, Petry, Weyman, et al.
Annals of Neurology
IL-9 alterations linked to Alzheimer's disease in African Americans
Wharton, Kollhoff, Gangishetti, et al.
American Journal of Clinical Nutrition
Lifestyle intervention modifies the effect of the MC4R genotype on changes in insulin resistance among women with prior gestational diabetes: Tianjin Gestational Diabetes Mellitus Prevention Program
Chen, Liu, Wang, et al.
Journal of the American Heart Association
Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study
Fadini, Frison, Simioni, et al.
Archivos Españoles de Urología
Inter-rater reliability of the digital palpation of pelvic floor muscle by the modified Oxford Grading Scale in continent and incontinent women
Romero-Cullerés, Jané-Feixas, Vilaseca-Grané, et al.
Lancet Diabetes & Endocrinology
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Mosenzon, Blicher, Rosenlund, et al.

Pages

HAB Central Earn honoraria and learn developments in medicine. For more than 25 years, the Healthcare Advisors Bureau (HAB) has gathered the opinions of professional healthcare providers.

Through HAB, the world of medicine has a respected and influential voice with government bodies, institutions, publishers, product manufacturers and providers of healthcare services.

Send feedback